Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
BAVA.CO
Strong BuyFull HouseAPPROVEBavarian Nordic A/S · Healthcare · Denmark · $2.5B · Avg Vol: $7M/d
Bavarian Nordic holds a near-monopoly position in critical vaccine markets during a period of heightened global health security concerns. With a 7.7% upward revision to forward-EPS and being the provider of a unique product during an internationally declared health crisis, the company demonstrates the pricing power and defensive moat required for this fund.
COMPANY DESCRIPTION
Bavarian Nordic A/S is a fully integrated biotechnology company specializing in the development, manufacturing, and commercialization of vaccines for infectious diseases and cancer. The company holds a unique position as a leading developer and supplier of smallpox and monkeypox vaccines, securing strategic contracts with governments globally. Bavarian Nordic is known for its proprietary MVA-BN vaccine platform, which provides a safe and effective viral vector for vaccine development.
FINANCIAL SUMMARY (DKK)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 3.2B | 7.1B | 5.7B | 6.2B | 25.6% | 6.4B | 5.9B | 5.6B | -5.0% |
| EPS (DKK) | -7.40 | -4.90 | 19.20 | 12.60 | 17.60 | -4.3% | 19.53 | 12.93 | 10.52 | -22.7% |
| Shares | — | 70.6M | 77.9M | 78.6M | 78.3M | +10.9% | 75.7M | — | — | — |
| Debt | — | 1.8B | 145.3M | 128.3M | 130.9M | -57.9% | 132.3M | — | — | — |
| Equity | — | 7.1B | 10.3B | 11.4B | 12.9B | 21.6% | — | — | — | — |
| Op CF | — | 220.1M | 1.1B | 1.9B | 2.7B | 131.3% | 1.4B | — | — | — |
| Inv CF | — | -877.4M | -945.6M | -1.9B | -2.5B | — | — | — | — | — |
| Fin CF | — | 635.8M | 735.8M | 55.8M | -114.4M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of BAVA.CO are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| BAVA.CO | Bavarian Nordic A/S(you) | $2.5B | 98 | Strong Buy |
| ZEAL.CO | Zealand Pharma A/S | $3.3B | 84 | Strong Buy |
| ALK-B.CO | ALK-Abelló A/S | $7.2B | 65 | Buy |
| GMAB.CO | Genmab A/S | $20.8B | 77 | Buy |
| SANION.ST | Saniona AB (publ) | $167M | 77 | Buy |
| GUBRA.CO | Gubra A/S | $990M | 34 | Sell |
| ASND | Ascendis Pharma A/S | $16.3B | 44 | Hold |
| HLUN-B.CO | H. Lundbeck A/S | $6.4B | 99 | Strong Buy |
| DEMANT.CO | Demant A/S | $9.3B | 90 | Strong Buy |
| AMBU-B.CO | Ambu A/S | $2.9B | 60 | Hold |
Peer medians: ROE 17.4% · P/E 23.1x · Gross margin 82.0%